$NTRA

Natera, Inc.

Natera is a diagnostics company that applies molecular and bioinformatics technology to genetic testing and disease management. Its three main areas are oncology, women’s health and organ health. Products include Signatera and Latitude for cancer monitoring, Altera for tumor profiling, Panorama prenatal screening, Horizon carrier screening, Prospera transplant rejection testing and Renasight genetic testing for kidney disease. Natera also offers Constellation, cloud software that lets licensed laboratories run molecular workflows and use its bioinformatics algorithms. Natera sells tests directly and distributes them through laboratory and distribution partners. It performs commercial testing in its CLIA-certified laboratories, offers Constellation under license to laboratories, and provides tests for clinical use and, in some cases, research use. Its products are offered in over 80 countries. Natera is headquartered in Austin, Texas, with laboratory facilities in Austin, San Carlos, California and Boulder, Colorado.

AlphAI earnings readthird quarter of 2026 · NOV 5Natera Reports Third Quarter 2026 Financial ResultsVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

4
4
1
—
$14.4M
Sheena Jonathan
100%
See all $NTRA insider activity →
Med

Why Is Natera Stock Up Nearly 41% Since May?

Natera (NTRA) stock rose 40.8% from May 20 to November 16, 2026, driven by strong revenue growth and raised forecasts. The company reported Q2 revenue of $752.8M (up 37.7% YoY) and Q3 revenue of $794M (up 34.1% YoY), with a narrowed operating loss margin. Natera also gained in organ transplant testing due to Medicare coverage. The stock's performance outpaced the S&P 500, which gained 0.3% over the same period.

Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029

Natera's CFO outlined plans to reach $6B revenue by 2029, citing growth in Signatera testing, Medicare coverage, and new patient acquisition. Signatera revenue is expected to exceed $1B this year, with a 2029 price target of $1,450. Natera is investing in R&D and clinical trials, with a potential U.S. launch of its colorectal cancer screening test in 2028-2029. The company is also targeting the Japanese market for Signatera.

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

NTRA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 9 news stories mentioning NTRA (Natera, Inc.). Coverage has skewed bullish: 4 bullish, 4 neutral, and 1 bearish.

Recent NTRA coverage spans financial news, earnings and insider activity.

In the last 30 days, NTRA insiders filed 83 SEC Form 4 transactions — no purchases and 83 sales ($14.4M). The most active reporter was Sheena Jonathan with 45 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving NTRA

AlphAI scores every news story that mentions NTRA with an AI model for sentiment and relevance, and aggregates insider trades from Natera, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NTRA

Score

Why Is Natera Stock Up Nearly 41% Since May?

Natera (NTRA) stock rose 40.8% from May 20 to November 16, 2026, driven by strong revenue growth and raised forecasts. The company reported Q2 revenue of $752.8M (up 37.7% YoY) and Q3 revenue of $794M (up 34.1% YoY), with a narrowed operating loss margin. Natera also gained in organ transplant testing due to Medicare coverage. The stock's performance outpaced the S&P 500, which gained 0.3% over the same period.

Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029

Natera's CFO outlined plans to reach $6B revenue by 2029, citing growth in Signatera testing, Medicare coverage, and new patient acquisition. Signatera revenue is expected to exceed $1B this year, with a 2029 price target of $1,450. Natera is investing in R&D and clinical trials, with a potential U.S. launch of its colorectal cancer screening test in 2028-2029. The company is also targeting the Japanese market for Signatera.

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

Stanley Druckenmiller’s Next 13F Likely Lands Monday. 3 Positions to Watch

Stanley Druckenmiller's Duquesne Family Office must file its Q3 13F by Monday, revealing holdings as of Sept. 30. Top positions in Q2 included Natera, Taiwan Semiconductor, and Insmed, with Natera being the largest at 19.9% of the portfolio. Analysts' average price targets for these stocks are 28% to 61% above current prices. Taiwan Semiconductor's sales have been record-high despite a stock price decline.

Related tickers